Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study

Annals of Surgical Oncology

Volumn 15, Issue 4, 2008, Pages 1183-1192

  DeBree, Eelco ^a   Rosing, Hilde ^b   Filis, Dimitris ^a   Romanos, John ^a   Melisssourgaki, Maria ^a   Daskalakis, Markos ^a   Pilatou, Maria ^a   Sanidas, Elias ^a   Taflampas, Panagiotis ^a   Kalbakis, Konstantinos ^a   Beijnen, Jos H ^b   Tsiftsis, Dimitris D ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; BLOOD SAMPLING; CANCER MORTALITY; CLINICAL ARTICLE; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; FEMALE; HUMAN; HYPERTHERMIC THERAPY; MORBIDITY; NEUTROPENIA; OVARY CANCER; PANCYTOPENIA; PERITONEAL FLUID LEVEL; THROMBOCYTOPENIA; WOUND INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; INTRAOPERATIVE PERIOD; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 40549129332     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9792-y     Document Type: Conference Paper

References (61)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30
2. McGuire WP III, Markman M. Primary ovarian cancer chemotherapy: current standards of care. Br J Cancer 2003; 89 suppl 3:S3-8
3. Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: a meta-analysis of multiple treatments. J Natl Cancer Inst 2006; 98:1655-63
4. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphomide for stage III ovarian cancer. New Engl J Med 1996; 335:150-5
5. Markman M, Bundy B, Alberts DS, et al. Phase III study of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-7
6. de Bree E, Theodoropoulos PA, Rosing H, et al. Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev 2006; 32:471-82
7. Armstrong DK, Bundy BN, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Eng J Med 2006; 354:34-43
8. Trimble EL, Christian MC. Intraperitoneal chemotherapy for women with advanced epithelial ovarian carcinoma. Gynecol Oncol 2006; 100:3-4
9. de Bree E, Tsiftsis DD. Principles of perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis. Recent Results Cancer Res 2007; 169:39-51
10. Dedrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J Natl Cancer Inst 1997; 89:480-7
11. Witkamp AJ, de Bree E, van Goethem AR, et al. Rationale and technique of intraoperative hyperthermic intraperitoneal chemotherapy. Cancer Treat Rev 2001; 27:365-74
12. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin North Am 2003; 12; 689-701
13. Markman M. Intraperitoneal Taxol. Cancer Treat Res 1996; 81:1-5
14. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 1992; 10:1485-91
15. Fushida S, Furui N, Kinami S, et al. [Pharmacologic study of intraperitoneal paclitaxel in gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho 2002; 29:2164-7
16. Hofstra LS, Bos AME, de Vries EGE, et al. Kinetic modelling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer. Gynecol Oncol 2002; 85:517-23
17. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995; 13:2961-7
18. Rupniak HY, Whelan RD, Hill BT. Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro. Int J Cancer 1983; 32:7-12
19. Michalakis J, Georgatos SD, de Bree E, et al. Short term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long term inhibition of cell proliferation and cell death in vitro. Ann Surg Oncol 2007; 14:1220-8
20. Michalakis J, Georgatos SD, Romanos J, et al. Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. Cancer Chemother Pharmacol 2005; 56:615-22
21. de Bree E, Rosing H, Beijnen JH, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. Anticancer Drugs 2003; 14:103-10
22. de Bree E, Romanos J, Michalakis J, et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003; 23:3019-28
23. Tsiftsis D, de Bree E, Romanos J, et al. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. Arch Surg 1999; 134:545-9
24. Stokvis E, Ouwehand M, Nan LG, et al. A simple and sensitive assay for the quantificative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry. J Mass Spectrom 2004; 39:1506-12
25. Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47:2486-93
26. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86:18-24
27. Omura GA, Brady MF, Look KY, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an Intergroup study. J Clin Oncol 2003; 21:2843-8
28. Reed E, Bitton R, Sarosy G, et al. Paclitaxel dose intensity. J Infus Chemother 1996; 6:59-63
29. Takimoto CH, Rowinsky EK. Dose-intense paclitaxel: déjà vu all over again? J Clin Oncol 2003; 21; 2810-4
30. Mohamed F, Marchetti P, Stuart OA, et al. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions. Cancer Chemother Pharmacol 2003; 52:405-10
31. Innocenti F, Danesi R, Di Paolo A, et al. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug Metab Dispos 1995; 23:713-7
32. Ohashi N, Kodera Y, Nakanishi H, et al. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastases as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 2005; 27:637-44
33. Kuh H-J, Jang S, Wientjes JM, et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacol Exper Ther 1999; 290:871-80
34. Mohamed F, Marchetti P, Stuart OA, et al. A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 2003; 29:261-5
35. de Bree E, Tsiftsis DD. Experimental and pharmacokinetic studies in intraperitoneal chemotherapy: from laboratory bench to bedside. Recent Results Cancer Res 2007; 169:53-73
36. Fushida S, Nao F, Kinami S, et al. [Pharmacologic study of intraperitoneal docetaxel in gastric cancer with peritoneal dissemination]. Gan To Kagaku Ryoho 2002; 29:1759-63
37. Morgan RJ, Doroshow JH, Synold T, et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin Cancer Res 2003; 9:5896-901
38. Yokogawa K, Jin M, Furui N, et al. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles. J Pharm Pharmacol 2004; 56:629-34
39. Gelderblom H, Verweij J, van Zomeren DM, et al. Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res 2002; 8:1237-41
40. Mross K, Holländer N, Hauns B, et al. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 2000; 45:463-70
41. Nannan Panday VR, ten Bokkel Huinink WW, Vermorken JB, et al. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion. Pharmacol Res 1999; 40:67-74
42. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13:180-90
43. Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 1993; 11:2127-35
44. Leal BZ, Meltz ML, Mohan N, et al. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999; 15:225-36
45. Rietbroek RC, Katschinski DM, Reijers MH, et al. Lack of thermal enhancement for taxanes in vitro. Int J Hyperthermia 1997; 13:525-33
46. Knox JD, Mitchel RE, Brown DL. Effects of taxol and taxol/hyperthermia treatments on the functional polarization of cytotoxic T lymphocytes. Cell Motil Cytoskeleton 1993; 24:129-38
47. van Bree C, Savoneije JH, Franken NA, et al. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 2000; 16:739-44
48. Othman T, Goto S, Lee JB, et al. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001; 62:208-12
49. Cividalli A, Cruciani G, Livdi E, et al. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys 1999; 44:407-12
50. Cividalli A, Livdi E, Ceciarelli F, et al. Hyperthermia and paclitaxel-epirubicin chemotherapy: enhanced cytotoxic effect in a murine mammary adenocarcinoma. Int J Hyperthermia 2000; 16:61-71
51. Sharma D, Chelvi TP, Kaur J, et al. Thermosensitive liposomal taxol formulation: heat-mediated targeted drug delivery in murine melanoma. Melanoma Res 1998; 8:240-4
52. Mohamed F, Marchettini P, Stuart OA, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003; 10:463-8
53. Hager ED, Dziambor H, Hohmann D, et al. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer. Int J Gynecol Cancer 2001; 11(suppl. 1):57-63
54. Piso P, Dahlke M-H, Loss M, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis. World J Surg Oncol 2004; 2:21-8
55. Ryu KS, Kim JH, Ko HS, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004; 94:325-32
56. Zanon C, Clara R, Chiappino I, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004; 28:1040-5
57. Gori J, Castano R, Toziano M, et al. Intraperitoneal hyperthermic chemotherapy in ovarian cancer. Int J Gynecol Cancer 2005; 15:233-9
58. Raspagliesi F, Kusamara S, Campos, et al. Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 2006; 32:671-5
59. Helm CW, Randall-Whites L, Martin RS III, et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 2007; 105:90-6
60. Rufian S, Munoz-Casares FC, Briceno J, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent and primary ovarian cancer. J Surg Oncol 2006; 94:316-24
61. Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol 2007; 106:193-209